IBB
iShares Biotechnology ETF (IBB)
IBB (iShares Biotechnology ETF) charges a 0.44% expense ratio. On a $10,000 investment that is about $44.00 per year in fund fees, or about $440 per year on $100,000. The fee is deducted automatically from the fund's value, not billed separately. See how expense ratios work →
Performance (data as of Jul 14, 2026): YTD +12.7% · 1-year +45.6% · 3-year +17.0% annualized · 5-year +4.2% annualized. Dividend yield 0.22%. $9.1B in assets. Past performance does not guarantee future results.
iShares Nasdaq Biotech ETF: about 350 biotech and pharmaceutical companies, market-cap weighted, at 0.44%. Amgen, Gilead, and Regeneron dominate the weight. More stable than XBI because large-cap pharma companies have diversified drug portfolios. For biotech with some ballast, IBB. For full small-cap biotech risk including early-stage clinical companies, XBI.
✓ Who it's actually for
! Know this before you buy
Editorial opinion based on documented fund characteristics, not personalized investment advice. ETF BFF is not a registered investment advisor.
📖 New to ETF fact sheets? Here's how to use this page:
📈 Performance history
Annualized where notedReturns are price-based and exclude dividend reinvestment. Total return will typically be higher by approximately the fund's annual yield. Past performance does not guarantee future results.
How does this ETF stack up against the competition?
⚖️ Compare side by side →🛡️ Risk and volatility
✅ Before you buy this ETF
Check these boxes before buying. Good investing habits matter more than picking the right fund.
❓ Questions people actually ask about this ETF
-
IBB's expense ratio is 0.44% per year. On a $10,000 investment, that is roughly $44.00 per year in fund fees, automatically deducted from the fund's NAV, not billed separately. What expense ratios cover, and what a good one looks like →
-
iShares Nasdaq Biotech ETF: about 350 biotech and pharmaceutical companies, market-cap weighted, at 0.44%. Amgen, Gilead, and Regeneron dominate the weight. More stable than XBI because large-cap pharma companies have diversified drug portfolios. For biotech with some ballast, IBB. For full small-cap biotech risk including early-stage clinical companies, XBI. Past performance does not guarantee future results. Educational only, not personalized investment advice. ETF BFF is not a registered investment advisor.
-
IBB returned +45.6% over the trailing 12 months. Past performance does not guarantee future results. ETF returns fluctuate with market conditions. Educational only, not personalized investment advice.
-
IBB (iShares Biotechnology ETF) has $9.1B in assets under management. AUM is a measure of fund size and liquidity. Larger funds generally have tighter bid-ask spreads and are less likely to close. It is not a measure of quality or expected returns.
-
IBB has a trailing 12-month dividend yield of 0.22%. ETF dividends are paid to shareholders based on distributions collected from the underlying holdings. Dividend payments are not guaranteed and can vary each quarter based on fund holdings and market conditions. Educational only, not personalized investment advice.
-
Use the ETF BFF comparison tool at etfbff.com/research/compare/ to run a side-by-side analysis of IBB against similar ETFs, covering expense ratios, holdings overlap, performance history, and our plain-English verdict on which one fits your goals.
All answers are educational and general in nature, not personal financial advice. Always verify data with the fund issuer and do your own research before investing.